Eyenovia (NASDAQ:EYEN) Receives “Neutral” Rating from LADENBURG THALM/SH SH

LADENBURG THALM/SH SH restated their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Monday morning, MarketBeat reports.

A number of other equities analysts have also recently issued reports on EYEN. HC Wainwright cut Eyenovia from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $12.00 to $2.00 in a report on Monday. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th. Finally, William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th.

Eyenovia Price Performance

Shares of Eyenovia stock opened at $0.09 on Monday. The stock has a market cap of $5.92 million, a price-to-earnings ratio of -0.13 and a beta of 1.75. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a 50 day moving average price of $0.46 and a 200-day moving average price of $0.69. Eyenovia has a one year low of $0.08 and a one year high of $2.57.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the previous year, the company posted ($0.18) earnings per share. Equities analysts expect that Eyenovia will post -0.5 EPS for the current year.

Insider Transactions at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares in the company, valued at $47,268.39. This represents a 151.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eyenovia in the second quarter worth about $26,000. Ground Swell Capital LLC purchased a new stake in shares of Eyenovia in the second quarter worth about $27,000. Nations Financial Group Inc. IA ADV boosted its stake in shares of Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Financial Management Network Inc. purchased a new stake in shares of Eyenovia in the third quarter worth about $39,000. Finally, SkyView Investment Advisors LLC purchased a new stake in shares of Eyenovia in the second quarter worth about $87,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.